{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:02:15Z","timestamp":1793318535067,"version":"4.5.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T00:00:00Z","timestamp":1730332800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>STUDY QUESTION<\/jats:title>\n                    <jats:p>What are the reproductive outcomes of patients who cryopreserved oocytes or embryos in the context of fertility preservation in the Netherlands?<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>SUMMARY ANSWER<\/jats:title>\n                    <jats:p>This study shows that after a 10-year follow-up period, the utilization rate to attempt pregnancy using cryopreserved oocytes or embryos was 25.5% and the cumulative live birth rate after embryo transfer was 34.6% per patient.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>WHAT IS KNOWN ALREADY<\/jats:title>\n                    <jats:p>Fertility preservation by freezing oocytes or embryos is an established treatment for women with a risk of premature ovarian failure (caused by a benign or oncological disease) or physiological age-related fertility decline. Little is known about the success of cryopreservation, the utilization rate of oocytes or embryos, or the live birth rates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>STUDY DESIGN, SIZE, DURATION<\/jats:title>\n                    <jats:p>A retrospective observational study was performed in the Netherlands. Data were collected between 2017 and 2019 from 1112 women who cryopreserved oocytes or embryos more than 2 years ago in the context of fertility preservation in 10 IVF centers in the Netherlands.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PARTICIPANTS\/MATERIALS, SETTING, METHODS<\/jats:title>\n                    <jats:p>A total of 1112 women were included in this study. Medical files and patient databases were used to extract data. Women were categorized based on indication of fertility preservation: oncological, benign, or non-medical. To indicate statistical differences the t-test or Mann\u2013Whitney U test was used. Kaplan\u2013Meier analyses were used for time endpoints, and log-rank analyses were used to assess statistical differences. The study protocol was approved by the medical ethics committee.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MAIN RESULTS AND THE ROLE OF CHANCE<\/jats:title>\n                    <jats:p>Fertility preservation cycles have been performed increasingly over the years in the Netherlands. In the first years, less than 10 cycles per year were performed, increasing to more than 300 cycles per year 10 years later. Initially, embryos were frozen in the context of fertility preservation. In later years, cryopreservation of oocytes became the standard approach. Cryopreservation of oocytes versus embryos resulted in comparable numbers of used embryos (median of 2) for transfer and comparable live birth rates (33.9% and 34.6%, respectively). The 5-year utilization rate was 12.3% and the 10-year utilization rate was 25.5%. The cumulative clinical pregnancy rate was 35.6% and the cumulative live birth rate was 34.6% per patient. Those who had fertility preservation due to benign diseases returned earlier to use their cryopreserved embryos or oocytes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>LIMITATIONS, REASONS FOR CAUTION<\/jats:title>\n                    <jats:p>The follow-up period after the fertility preservation procedure varied between patients in this study and not all frozen oocytes or embryos had been used at the end of this study. This might have led to underestimated outcomes reported in this study. Furthermore, intention to treat cannot be fully determined since women who started the fertility preservation procedure without success (cancellation due to low response) were not included in this study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>WIDER IMPLICATIONS OF THE FINDINGS<\/jats:title>\n                    <jats:p>This study provides data on the reproductive outcomes after various indications of fertility preservation. This knowledge can be informative for professionals and future patients to improve counseling and informed decision making regarding ovarian stimulation in the context of fertility preservation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>STUDY FUNDING\/COMPETING INTEREST(S)<\/jats:title>\n                    <jats:p>No funding was obtained for this study. The authors have no conflicts of interest to declare related to this study. V.T.H. received grants paid to the institute for studies outside the present work from AstraZeneca, Gilead, Novartis, Eli Lily, Pfizer, and Daiichi Sankyo. V.T.H. received consulting fees from Eli Lily outside the present work. M.G. received grants paid to the institute for studies outside the present work from Guerbet and Ferring. E.M.E.B. received a grant from The Dutch Network of Fertility Preservation for a study outside the present work.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>TRIAL REGISTRATION NUMBER<\/jats:title>\n                    <jats:p>N\/A.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/humrep\/deae243","type":"journal-article","created":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T12:17:20Z","timestamp":1728994640000},"page":"2693-2701","source":"Crossref","is-referenced-by-count":15,"title":["Outcomes of female fertility preservation with cryopreservation of oocytes or embryos in the Netherlands: a population-based study"],"prefix":"10.1093","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3882-8036","authenticated-orcid":false,"given":"M Elena","family":"ter Welle-Butalid","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Maastricht University Medical Center , Maastricht,","place":["The Netherlands"]},{"name":"GROW\u2014School for Oncology and Reproduction, Maastricht University , Maastricht,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josien G","family":"Derhaag","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Maastricht University Medical Center , Maastricht,","place":["The Netherlands"]},{"name":"GROW\u2014School for Oncology and Reproduction, Maastricht University , Maastricht,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2898-9178","authenticated-orcid":false,"given":"Bo E","family":"van Bree","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Maastricht University Medical Center , Maastricht,","place":["The Netherlands"]},{"name":"GROW\u2014School for Oncology and Reproduction, Maastricht University , Maastricht,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingeborg J H","family":"Vriens","sequence":"additional","affiliation":[{"name":"GROW\u2014School for Oncology and Reproduction, Maastricht University , Maastricht,","place":["The Netherlands"]},{"name":"Department of Internal Medicine, Division of Medical Oncology, Maastricht University Medical Center , Maastricht,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari\u00ebtte","family":"Goddijn","sequence":"additional","affiliation":[{"name":"Center for Reproductive Medicine, Amsterdam UMC , Amsterdam,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2116-7363","authenticated-orcid":false,"given":"Eva M E","family":"Balkenende","sequence":"additional","affiliation":[{"name":"Center for Reproductive Medicine, Amsterdam UMC , Amsterdam,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catharina C M","family":"Beerendonk","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Radboud University Medical Center , Nijmegen,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M E","family":"Bos","sequence":"additional","affiliation":[{"name":"Department of Reproductive Medicine, University Medical Center Utrecht , Utrecht,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6794-2102","authenticated-orcid":false,"given":"Irene","family":"Homminga","sequence":"additional","affiliation":[{"name":"Center for Reproductive Medicine, University Medical Center Groningen , Groningen,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie H","family":"Benneheij","sequence":"additional","affiliation":[{"name":"Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynaecology, Erasmus University Medical Centre , Rotterdam,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H C","family":"van Os","sequence":"additional","affiliation":[{"name":"Department of Reproductive Medicine, Reinier de Graaf Hospital , Voorburg,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesper M J","family":"Smeenk","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Elisabeth-TweeSteden Hospital , Tilburg,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke O","family":"Verhoeven","sequence":"additional","affiliation":[{"name":"Center for Reproductive Medicine, Amsterdam UMC , Amsterdam,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casandra C A W","family":"van Bavel","sequence":"additional","affiliation":[{"name":"Isala Fertility Centre, Isala Clinics , Zwolle,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivianne C G","family":"Tjan-Heijnen","sequence":"additional","affiliation":[{"name":"GROW\u2014School for Oncology and Reproduction, Maastricht University , Maastricht,","place":["The Netherlands"]},{"name":"Department of Internal Medicine, Division of Medical Oncology, Maastricht University Medical Center , Maastricht,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron J T","family":"van Golde","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Maastricht University Medical Center , Maastricht,","place":["The Netherlands"]},{"name":"GROW\u2014School for Oncology and Reproduction, Maastricht University , Maastricht,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,10,30]]},"reference":[{"key":"2024121017575409800_deae243-B1","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1007\/s10815-021-02133-0","article-title":"Conception after chemotherapy: post-chemotherapy method of conception and pregnancy outcomes in breast cancer patients","volume":"38","author":"Abel","year":"2021","journal-title":"J Assist Reprod Genet"},{"key":"2024121017575409800_deae243-B2","article-title":"ESHRE guideline: female fertility preservation","volume":"2020","author":"Anderson","year":"2020","journal-title":"Hum Reprod Open"},{"key":"2024121017575409800_deae243-B3","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.rbmo.2018.07.005","article-title":"Reproductive outcomes after oocyte banking for fertility preservation","volume":"37","author":"Balkenende","year":"2018","journal-title":"Reprod Biomed Online"},{"key":"2024121017575409800_deae243-B4","article-title":"ESHRE guideline: ovarian stimulation for IVF\/ICSI (dagger)","volume":"2","author":"Bosch","year":"2020","journal-title":"Hum Reprod Open"},{"key":"2024121017575409800_deae243-B5","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.fertnstert.2021.02.006","article-title":"Oocyte vitrification for fertility preservation for both medical and nonmedical reasons","volume":"115","author":"Cobo","year":"2021","journal-title":"Fertil Steril"},{"key":"2024121017575409800_deae243-B7355633","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1093\/humrep\/dey321","article-title":"Elective and Onco-fertility preservation: factors related to IVF outcomes","volume":"33","author":"Cobo","year":"2018","journal-title":"Hum Reprod"},{"key":"2024121017575409800_deae243-B6","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s10815-018-1303-5","article-title":"Achieving the \u201cideal\u201d family size at advanced reproductive ages through oocyte cryopreservation","volume":"36","author":"DeVore","year":"2019","journal-title":"J Assist Reprod Genet"},{"key":"2024121017575409800_deae243-B7","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.fertnstert.2018.02.127","article-title":"To freeze or not to freeze: decision regret and satisfaction following elective oocyte cryopreservation","volume":"109","author":"Greenwood","year":"2018","journal-title":"Fertil Steril"},{"key":"2024121017575409800_deae243-B8","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1093\/humrep\/dex314","article-title":"Survey of reproductive experiences and outcomes of cancer survivors who stored reproductive material before treatment","volume":"32","author":"Hammarberg","year":"2017","journal-title":"Hum Reprod"},{"key":"2024121017575409800_deae243-B9","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s00404-010-1772-y","article-title":"Fertility preservation in &gt;1,000 patients: patient\u2019s characteristics, spectrum, efficacy and risks of applied preservation techniques","volume":"283","author":"Lawrenz","year":"2011","journal-title":"Arch Gynecol Obstet"},{"key":"2024121017575409800_deae243-B10","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1200\/JCO.2013.49.2678","article-title":"Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update","volume":"31","author":"Loren","year":"2013","journal-title":"J Clin Oncol"},{"key":"2024121017575409800_deae243-B11","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/humrep\/dead267","article-title":"A 10-year follow-up of reproductive outcomes in women attempting motherhood after elective oocyte cryopreservation","volume":"39","author":"Loreti","year":"2024","journal-title":"Hum Reprod"},{"key":"2024121017575409800_deae243-B12","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1001\/jamaoncol.2020.5957","article-title":"Reproductive outcomes after breast cancer in women with vs without fertility preservation","volume":"7","author":"Marklund","year":"2021","journal-title":"JAMA Oncol"},{"key":"2024121017575409800_deae243-B13","doi-asserted-by":"crossref","first-page":"VIII705","DOI":"10.1093\/annonc\/mdy424.006","article-title":"Pregnancies after breast cancer: is there a real need for fertility preservation? Results from the ARTEMIS cohort of 60 young patients","volume":"29","author":"Martin-Babau","year":"2018","journal-title":"Ann Oncol"},{"key":"2024121017575409800_deae243-B14","first-page":"1802","article-title":"Update on fertility preservation from the Barcelona International Society for Fertility Preservation\u2013ESHRE\u2013ASRM 2015 expert meeting: indications, results and future perspectives","volume":"32","author":"Martinez","year":"2017","journal-title":"Fertil Steril"},{"key":"2024121017575409800_deae243-B15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/humrep\/der364","article-title":"Elective oocyte cryopreservation: who should pay?","volume":"27","author":"Mertes","year":"2012","journal-title":"Hum Reprod"},{"key":"2024121017575409800_deae243-B16","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10549-020-06031-4","article-title":"Predictors and outcomes in breast cancer patients who did or did not pursue fertility preservation","volume":"186","author":"Moravek","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"2024121017575409800_deae243-B17","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1200\/JCO.2018.78.1914","article-title":"Fertility preservation in patients with cancer: ASCO clinical practice guideline update","volume":"36","author":"Oktay","year":"2018","journal-title":"J Clin Oncol"},{"key":"2024121017575409800_deae243-B18","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1200\/JCO.2014.59.3723","article-title":"Fertility preservation success subsequent to concurrent aromatase inhibitor treatment and ovarian stimulation in women with breast cancer","volume":"33","author":"Oktay","year":"2015","journal-title":"J Clin Oncol"},{"key":"2024121017575409800_deae243-B19","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1056\/NEJMoa2212856","article-title":"Interrupting endocrine therapy to attempt pregnancy after breast cancer","volume":"388","author":"Partridge","year":"2023","journal-title":"N Engl J Med"},{"key":"2024121017575409800_deae243-B20","doi-asserted-by":"crossref","first-page":"vi160","DOI":"10.1093\/annonc\/mdt199","article-title":"Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Peccatori","year":"2013","journal-title":"Ann Oncol"},{"key":"2024121017575409800_deae243-B21","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.fertnstert.2012.09.028","article-title":"Mature oocyte cryopreservation: a guideline","volume":"99","author":"Practice Committees of the American Society for Reproductive Medicine, Society for Assisted Reproductive Technology","year":"2013","journal-title":"Fertil Steril"},{"key":"2024121017575409800_deae243-B22","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/aogs.13559","article-title":"A prospective study of women and girls undergoing fertility preservation due to oncologic and non-oncologic indications in Sweden-Trends in patients\u2019 choices and benefit of the chosen methods after long-term follow up","volume":"98","author":"Rodriguez-Wallberg","year":"2019","journal-title":"Acta Obstet Gynecol Scand"},{"key":"2024121017575409800_deae243-B23","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1093\/humrep\/des131","article-title":"Reproductive potential of a metaphase II oocyte retrieved after ovarian stimulation: an analysis of 23 354 ICSI cycles","volume":"27","author":"Stoop","year":"2012","journal-title":"Hum Reprod"},{"key":"2024121017575409800_deae243-B24","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejogrb.2023.12.009","article-title":"Considerations of breast cancer survivors to return for embryo transfer after fertility preservation: a qualitative study","volume":"293","author":"Ter Welle-Butalid","year":"2023","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2024121017575409800_deae243-B25","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1007\/s10815-019-01615-6","article-title":"Counseling young women with early breast cancer on fertility preservation","volume":"36","author":"Ter Welle-Butalid","year":"2019","journal-title":"J Assist Reprod Genet"},{"key":"2024121017575409800_deae243-B26","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1007\/s10815-022-02633-7","article-title":"Clinical outcome of planned oocyte cryopreservation at advanced age","volume":"39","author":"Tsafrir","year":"2022","journal-title":"J Assist Reprod Genet"},{"key":"2024121017575409800_deae243-B27","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s10549-020-05598-2","article-title":"Preserving fertility in young women undergoing chemotherapy for early breast cancer; the Maastricht experience","volume":"181","author":"Vriens","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"2024121017575409800_deae243-B28","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.fertnstert.2012.02.015","article-title":"A persistent misperception: assisted reproductive technology can reverse the \u201caged biological clock\u201d","volume":"97","author":"Wyndham","year":"2012","journal-title":"Fertil Steril"}],"container-title":["Human Reproduction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/humrep\/article-pdf\/39\/12\/2693\/60931530\/deae243.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/humrep\/article-pdf\/39\/12\/2693\/60931530\/deae243.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T13:12:57Z","timestamp":1733836377000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/humrep\/article\/39\/12\/2693\/7853505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,30]]},"references-count":29,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,10,30]]},"published-print":{"date-parts":[[2024,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/humrep\/deae243","relation":{},"ISSN":["0268-1161","1460-2350"],"issn-type":[{"value":"0268-1161","type":"print"},{"value":"1460-2350","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,10,30]]}}}